The Lancet (the-lancet)

Journal positioning

The Lancet is one of the world's oldest and most influential general medical journals, published by Elsevier. It publishes practice-changing and policy-changing clinical and global-health evidence, with an explicit commitment to health equity, global burden of disease, and the social determinants of health. The readership spans clinicians, public-health practitioners, policymakers, and health systems researchers worldwide. Papers that merely confirm existing practice without shifting guidelines or informing policy do not belong here.

This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the publisher's own site or submission system.

When to trigger

• The author names The Lancet as the target venue for a clinical trial, systematic review, or global-health analysis.
• A manuscript has potential practice- or policy-changing implications but needs framing around equity, global-health burden, or health-systems impact.
• A clinical-medicine paper needs to distinguish The Lancet's editorial culture from NEJM or JAMA before deciding where to submit.
• The author needs The Lancet's desk-reject risks and credible alternatives before submitting.

Scope & topic fit

• Large, well-powered randomised controlled trials with definitive superiority or non-inferiority results affecting clinical practice at scale.
• Systematic reviews and meta-analyses (PRISMA-compliant) that resolve a contested clinical question or establish a new evidence base.
• Global-health burden analyses, disease modelling, and epidemiological surveillance with policy implications for low- and middle-income countries.
• Health equity research: interventions or analyses addressing disparities across geography, income, race, sex, or other social determinants.
• Public-health emergencies, outbreak investigations, and pandemic-response science that reaches a global clinical and policy audience.
• Landmark observational cohort studies with prospective design and precise, adequately adjusted effect estimates.

Method & evidence bar

• Randomised trials must be pre-registered (ClinicalTrials.gov or WHO ICTRP equivalent), follow CONSORT reporting in full, and have an independent data-safety monitoring board for longer-horizon studies.
• Systematic reviews and meta-analyses require PRISMA adherence; protocol registration in PROSPERO or equivalent is expected; GRADE assessment of evidence quality is strongly encouraged.
• Observational studies require STROBE reporting and explicit discussion of residual confounding; propensity-score or multivariable adjustment alone does not satisfy the standard.
• The significance bar is definitiveness or paradigm-shift at population scale, not statistical significance in a convenience sample.
• Ethics approval and participant informed-consent documentation are mandatory; ICMJE authorship criteria must be satisfied and author contributions declared.
• Data sharing: a data-sharing statement is required; sharing individual participant data (IPD) for trials is strongly encouraged and increasingly expected.

Structure & house style

• The Lancet uses article types including Articles, Letters, Correspondence, Comment, and Review; choose the type that matches scope and length—re-check current word limits.
• The abstract for an Article is structured (background, methods, findings, interpretation) and must close with a funding statement.
• The opening paragraph of an Article must situate the work in current practice and articulate the evidence gap the study fills.
• An "Added value of this study" summary panel (what is already known, what this study adds) is required for Articles and Reviews.
• Statistical reporting must include absolute as well as relative effect measures; confidence intervals are mandatory; p-values alone are insufficient.
• Figures should be colour-blind-friendly and publication-ready; maps showing global data are highly valued editorially.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the official source anchors for this journal family, then cite the current journal-specific page you checked.
• Search the live site for "The Lancet information for authors" and follow the current Elsevier/Lancet version.
• Re-check article type definitions and current word/figure limits; re-check abstract structure requirements and the "Added value" panel format.
• Confirm trial or review registration number, ethics approval reference, and informed-consent statement are included.
• Confirm the data-sharing statement specifies what data will be shared, when, how, and with whom.
• Re-check competing-interests declaration (all authors), funding disclosure, ICMJE author-contribution statement, and AI-use disclosure policy.
• Confirm CONSORT (trials) or PRISMA (reviews) or STROBE (observational) checklist is submitted as a supplementary file.
• Re-check open-access/APC options, licensing terms, and preprint policy (The Lancet permits preprints; confirm current guidance).
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• One sentence stating why this finding changes clinical practice, public-health policy, or health-equity understanding at a population level.
• The contribution is framed as definitive evidence, practice shift, or policy insight—not as a "first-ever" claim or a p-value.
• The introduction positions the paper against the most relevant prior evidence, with an explicit statement of the remaining evidence gap.
• Reporting guideline checklist (CONSORT/PRISMA/STROBE) is complete and attached; registration number is cited in the methods.
• The "Added value" panel is drafted and accurately distinguishes this study's contribution from the existing literature.
• Global-health or equity framing is authentic and data-supported, not appended as a rhetorical gesture.

Common desk-reject triggers

• Trials that are not pre-registered, lack a CONSORT flow diagram, or have a sample size powered only for a surrogate endpoint with no clinical-outcome data.
• Systematic reviews without PROSPERO registration or PRISMA adherence, or meta-analyses dominated by high-risk-of-bias studies without sensitivity analysis.
• Single-centre or small-sample studies that do not establish a definitively new finding at scale.
• Observational studies framed as causal without credible identification strategy, or with STROBE-non-compliant reporting.
• Absence of a data-sharing statement or an ethics-approval reference; missing ICMJE authorship contributions.
• Global-health framing that is superficial—"this matters globally" asserted without burden-of-disease data or LMICcontext.

Re-routing decision

• Clinically definitive but more specialised in disease area → the-lancet-oncology, the-lancet-infectious-diseases, or the-lancet-neurology for condition-specific practice change.
• US-centric clinical trial with a rigorous AMA-style structured abstract → jama or nejm.
• Methodologically rigorous but emphasis on open data, EBM critique, or patient/public involvement → the-bmj.
• Translational mechanism-to-trial story with biological depth → nature-medicine.
• Open-access public-health focus with lower significance bar → plos-medicine.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] The Lancet
[Topic tags] <2–3 closest topics>
[Method/evidence] <does trial registration / CONSORT / scale clear The Lancet's practice-change bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type/length / structured abstract / Added-value panel / reporting checklist / data sharing / ethics / disclosure>
[Re-route suggestion] <if not a fit, a better-matched venue>